CION Ameerpet
Pancreatic Cancer · Types, Location & Resectability · Reviewed by CION Oncologists
Pancreatic ductal adenocarcinoma — what the diagnosis actually means
PDAC is the tumour almost everyone means when they say “pancreatic cancer”. This page explains what it is, how it differs from the other pancreatic tumours, and how the resectability category on your scan — not the stage number — decides what happens next.
- The type on the report decides everything — adenocarcinoma and neuroendocrine tumours are separate diseases.
- Resectability outranks the stage number — whether the tumour can be removed shapes the plan.
- Position in the gland changes the picture — head tumours obstruct early; body and tail tumours declare late.
- Categories can move — treatment given first can shrink a borderline tumour into the operable group.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Pancreatic Ductal Adenocarcinoma Actually Is
If a report in front of you says pancreatic ductal adenocarcinoma, or simply PDAC, that is the tumour almost everyone means when they say pancreatic cancer without qualifying it. It begins in the cells lining the fine ducts that carry digestive juice through the gland towards the bowel. It is the commonest pancreatic malignancy by a wide margin, and it is the tumour that nearly every general article, news report and survival figure you will find online is actually describing.
That distinction matters more than it sounds. The pancreas gives rise to several genuinely different tumours. They do not behave alike, they are not staged alike, and they are not treated alike. Reading about the wrong one is a common and entirely avoidable source of distress in the first week after a diagnosis. Before anything else, find the exact wording on the pathology report. “Ductal adenocarcinoma” is a specific phrase, and so is “neuroendocrine tumour”.
Ductal adenocarcinoma is what oncologists call an exocrine tumour: it arises from the enzyme-and-duct side of the pancreas rather than from the hormone-producing islet cells. It provokes a dense fibrous reaction in the tissue around it, which is part of why it can be hard to see clearly on an ordinary scan and why a pancreatic-protocol study is used instead. It also tends to track along nerves and small vessels rather than sitting as a neat ball, which is why surgery is planned with wide clearance in mind and why the pathologist examines the specimen so carefully afterwards.
The rest of this page sets out how PDAC differs from the other pancreatic tumours, what its position in the gland changes, how the four resectability categories work, and what is worth reading off your own reports. For the wider picture — symptoms, diagnosis, treatment and support in one place — the complete pancreatic cancer guide covers the whole pathway.
Did you know? The WHO Classification of Tumours of the Digestive System treats pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumours as separate diseases rather than variants of one another. Ductal adenocarcinoma arises from duct epithelium and is graded by how closely the tumour still forms recognisable glands; neuroendocrine tumours arise from islet cells and are graded on a proliferation index and mitotic count. NCCN publishes a separate guideline for each. That is why a treatment protocol, a clinical study or a survival figure written for one of them tells you almost nothing about the other — and why the first genuinely useful question after a pancreatic diagnosis is not “what stage is it” but “which tumour is it”.
Know which one you have
How PDAC Differs From the Other Pancreatic Tumours
These are the distinctions most often blurred in the first fortnight after a diagnosis. Check each one against the wording on your own report rather than against how the diagnosis was summarised in conversation.
The default type
Ductal adenocarcinoma
Arises from the duct lining, accounts for the large majority of pancreatic cancers, and is the tumour that every unqualified article about pancreatic cancer is describing.
A different disease
Neuroendocrine tumour
Arises from islet cells, is graded on how quickly its cells are dividing rather than on gland formation, usually grows far more slowly and carries a considerably better outlook. Adenocarcinoma figures simply do not describe it.
Rare exocrine variant
Acinar cell carcinoma
An uncommon tumour of the enzyme-producing cells, with its own presentation and its own pathology. Acinar cell carcinoma of the pancreas explains how it differs.
The neighbouring structures
Ampullary and periampullary cancer
Tumours at the point where the bile and pancreatic ducts drain into the duodenum. They obstruct early, are usually found sooner and carry a better outlook — see ampullary and periampullary cancer.
Where it sits
Head, or body and tail
A tumour in the head sits against the bile duct and announces itself with painless jaundice — cancer in the head of the pancreas. A tumour in the body or tail has nothing to obstruct, so it is usually found later.
Down the microscope
Grade and differentiation
Well, moderately or poorly differentiated describes how closely the tumour still resembles normal duct tissue. How grade and differentiation affect the outlook takes that apart.
The axis that decides the plan
The Four Categories Your Report Will Use
PDAC is staged with the TNM system, but the decision about an operation is made on a separate axis called resectability — how far the tumour touches or surrounds the arteries and veins behind the pancreas. Pancreatic cancer staging set against resectability explains why both systems exist and how they line up.
| Category | What the scan shows | Where the operation sits | What usually happens first |
|---|---|---|---|
| Resectable | No contact with the major arteries, and at most limited contact with the vein that a surgeon could reconstruct. | An operation is possible as things stand. | Surgery, or a course of systemic treatment before it — what resectable pancreatic cancer means. |
| Borderline resectable | Limited contact with an artery, or vein involvement that would need reconstruction to clear. | Possible, but not straight away. | Chemotherapy first, then the vessels are re-imaged — what happens next with borderline resectable disease. |
| Locally advanced | The tumour surrounds a major artery, but there is no spread to distant organs. | Not removable at presentation. | Systemic treatment, sometimes with radiation, then reassessment — can locally advanced pancreatic cancer become operable? |
| Metastatic | Deposits beyond the pancreas, most often in the liver or the lining of the abdomen. | Surgery is not the aim; control and comfort are. | Systemic treatment and symptom care — where metastatic pancreatic cancer spreads and what stage 4 pancreatic cancer means. |
Categories are not permanent labels. A borderline tumour can shrink into the operable group after treatment, and a tumour that looked resectable on a scan can turn out otherwise once the abdomen is inspected. Ask which category you are in today, and ask what would move you into a different one.
Take this to your appointment
What to Read Off Your Own Reports
Eight things worth locating before the next consultation. None of them is a difficult question to ask, and each one changes what applies to you.
- The exact tumour type. Look for the words ductal adenocarcinoma. If the report says neuroendocrine tumour, acinar cell carcinoma or ampullary carcinoma instead, most of what you have been reading does not apply to your situation.
- Where it sits in the gland. Head, uncinate process, neck, body or tail. This changes how it presented, which operation would be considered, and how quickly jaundice needs dealing with.
- The resectability category. Written plainly in some CT reports and only implied in others. Ask for it in words rather than inferring it from the stage number.
- The grade. Well, moderately or poorly differentiated carries prognostic weight of its own, separate from stage — grade and differentiation in pancreatic cancer.
- Perineural and lymphovascular invasion. Very commonly reported in this tumour and often alarming to read. Perineural and vascular invasion in pancreatic cancer explains what it does and does not change.
- Node status and margins, if you have had surgery. How many nodes were examined, how many were involved, and whether the pathologist called the margins clear.
- The baseline CA 19-9. One reading on its own says little. The trend across successive tests is the part that informs anything.
- The follow-up plan. Ask at the beginning how a recurrence would be picked up, not at the end — how recurrent pancreatic cancer is found sets out what is watched and when.
If you are holding a scan report and a pathology report and cannot make them agree with each other, bring both in. We will read them with you and say plainly what they establish and what is still open. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The First Question Is Which Tumour, Not Which Stage
Your pathology report and your pancreatic-protocol scan settle more than anything you will read tonight.
What actually happens
From a PDAC Diagnosis to an Actual Plan
-
A pancreatic-protocol contrast CT
Not an ordinary abdominal scan. The contrast timing is set so that the tumour’s relationship to the arteries and veins behind the pancreas can be described precisely. This one study drives the resectability category.
Ordered and reported in-house at CION -
Tissue confirmation
An endoscopic ultrasound with a fine-needle sample confirms that this is ductal adenocarcinoma and not one of the other pancreatic tumours. The pathology report, not the scan, settles the type.
Coordinated with specialist endoscopy partners -
Relieving jaundice, where the head is involved
If bilirubin is high, a stent placed at ERCP drains the blocked bile duct so that treatment can start safely. This is done before, not instead of, the rest of the workup.
Coordinated with specialist endoscopy partners -
Completing the staging picture
Liver MRI clarifies indeterminate spots. Functional imaging and, in selected cases, a staging laparoscopy are used where the answer would change the plan rather than routinely.
MRI in-house; PET-CT and staging laparoscopy coordinated -
The case is discussed as a team
Imaging, pathology, nutrition and general fitness are reviewed together rather than by one doctor alone, so the plan reflects what medical oncology, radiation oncology and the surgical partners each think is achievable.
HPB tumour board at CION -
The plan is set, with its decision points written down
Combination chemotherapy, chemoradiation or SBRT is planned around the category, with the reassessment scan agreed in advance. Pancreatic cancer treatment in Hyderabad sets out the options in full.
Systemic therapy and radiation in-house at CION -
Nutrition, enzymes and pain from the first week
Weight loss and fat malabsorption are part of this disease, not a side issue. Pancreatic enzyme replacement, dietetic input and proper pain control start alongside treatment, not after it.
In-house at CION
Plainly stated
What CION Delivers, and What Is Coordinated
Being clear about this at the start saves a difficult conversation later. Your first consultation is free and lasts 45 minutes, and it is a genuine review of your reports rather than a booking appointment.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient; and systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI and MRCP, CA 19-9 and routine bloods; genetic counselling; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.
Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, including the Whipple procedure and distal or total pancreatectomy; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.
Both things are true
What the Diagnosis Settles, and What It Does Not
A diagnosis of pancreatic ductal adenocarcinoma settles the tumour type, and therefore which body of evidence, which guideline and which treatment track apply to you. That is genuinely useful, and it is the reason this page exists. It does not, on its own, settle the question everyone actually wants answered.
This is a serious cancer and it is often found late, because the pancreas sits deep in the abdomen and a tumour in the body or tail has nothing to obstruct until it is large. Saying otherwise would be dishonest and you would see through it. But the parts that are genuinely open are open. Cure is possible when the tumour is found early, can be removed completely and is followed by chemotherapy. Systemic treatment given first can shrink a borderline resectable tumour into the operable group. And even where an operation is never on the table, treatment aimed at control and at good symptom relief changes how people live with the disease.
What decides most of it is the category on your scan, the type on your pathology report and how well you are in yourself — not the headline you read on the night you were told. Get those three straight, then ask what would change each of them.
Bring the scan report and the pathology report to the first appointment. Between them they answer more than anything you will find online. Book a free consultation or call 1800 202 8726.
Take the next step
Get the Type and the Category Straight
We walk this journey with you, with the time to explain what your own reports actually say.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Pancreatic ductal adenocarcinoma — your questions answered
What is pancreatic ductal adenocarcinoma?
Pancreatic ductal adenocarcinoma, usually shortened to PDAC, is a cancer that begins in the cells lining the small ducts running through the pancreas. Those ducts carry digestive juice from the gland into the bowel. It is an exocrine tumour, meaning it comes from the enzyme-and-duct side of the pancreas rather than from the hormone-producing islet cells. It is by a wide margin the commonest form of pancreatic cancer, which is why almost every general article about pancreatic cancer is describing this tumour even when it does not say so. It has a characteristic dense fibrous reaction in the surrounding tissue, and it tends to spread along nerves and small vessels rather than staying as a discrete lump. Both of those shape how it is imaged, how it is operated on, and how the specimen is reported afterwards.
Is PDAC the same thing as pancreatic cancer?
In everyday conversation, yes, and that is exactly where the confusion starts. Pancreatic cancer is an umbrella term for several different diseases arising in the same organ, and ductal adenocarcinoma is only the commonest of them. Pancreatic neuroendocrine tumours, acinar cell carcinoma, and ampullary or periampullary cancers each behave differently, are staged on their own systems, and are treated along different pathways. If someone tells you they have pancreatic cancer, the useful follow-up question is which type the pathology report names. Until that is confirmed on tissue, general reading is at best approximate and at worst about a completely different disease from the one in front of you.
How is PDAC different from a pancreatic neuroendocrine tumour?
They are separate diseases that happen to share an organ. Ductal adenocarcinoma arises from duct lining and is graded by how closely it still forms recognisable glands. A neuroendocrine tumour arises from islet cells and is graded on a proliferation index and a mitotic count. Neuroendocrine tumours usually grow far more slowly, are often found incidentally, and carry a considerably better outlook. They are staged on their own system, and international guidance covers them under a separate guideline. Practically, this means outlook figures, treatment protocols and study results written for adenocarcinoma do not describe a neuroendocrine tumour at all. If your report says neuroendocrine tumour, most of what you have read about pancreatic cancer needs setting aside.
Does it matter whether the tumour is in the head, the body or the tail?
It matters a great deal, in two ways. First, it changes how the tumour showed itself. A tumour in the head sits against the bile duct, so it often causes painless jaundice while it is still relatively small, which is why head tumours are sometimes caught earlier. A tumour in the body or tail has nothing to obstruct, so it tends to declare itself later, with weight loss, back pain or new diabetes. Second, it changes which operation is even under discussion, since removing the head of the pancreas and removing the tail are quite different procedures with different recoveries. The position is stated in the scan report and is worth confirming in plain words at your next appointment.
What do resectable, borderline resectable and locally advanced mean on my report?
They describe how far the tumour touches the major blood vessels behind the pancreas, and therefore whether an operation is possible. Resectable means the arteries are clear and any vein contact could be reconstructed, so surgery is on the table now. Borderline resectable means there is limited arterial contact, or vein involvement that would need reconstruction, so treatment is usually given first and the vessels are then re-imaged. Locally advanced means the tumour surrounds a major artery but has not spread to distant organs, so it is not removable at presentation. Metastatic means deposits elsewhere, most often in the liver. These categories are assigned on the pancreatic-protocol scan, and they can change after treatment.
Why is pancreatic ductal adenocarcinoma so often found late?
Three things work together. The pancreas lies deep in the abdomen behind the stomach, so a tumour can grow without being felt and without showing on an ordinary ultrasound. The early symptoms are ordinary ones: vague upper abdominal discomfort, indigestion, tiredness, gradual weight loss, back pain, or new diabetes in someone who was not expected to develop it. Every one of those has a long list of far more common explanations, so they are reasonably attributed elsewhere first. And unlike breast or cervical cancer, there is no population screening programme for pancreatic cancer in the general public. The exception is painless jaundice, which obstructs early and should always be checked in the same week rather than watched.
What does CION do for someone newly diagnosed with PDAC, and what happens at the first visit?
The first consultation is free, lasts 45 minutes and is a proper review of your documents rather than a booking slot. Bring every scan disc, pathology report and blood result you have. A medical oncologist reads them with you, tells you which tumour type is confirmed and which is still assumed, names the resectability category, and says what is missing before a plan can be made. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief and psycho-oncology are delivered by CION across 35+ centres. Pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy and functional imaging are coordinated with specialist HPB and endoscopy partner centres and may be billed there. We tell you which is which before anything is booked.
Medical disclaimer: This page explains what pancreatic ductal adenocarcinoma is, how it is distinguished from the other pancreatic tumours, and how resectability categories are assigned. It is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and the WHO classification of digestive system tumours. It is general information and deliberately states no survival figure, because no published figure describes an individual; your own diagnosis, category and plan should be confirmed with your treating team. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling, nutrition and pancreatic enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.